New target discovered for treatment of cancer

Researchers at Karolinska Institutet have discovered a new way of blocking the formation of blood vessels and halting the growth of tumours in mice. A substance that exploits this mechanism could be developed into a new treatment for cancer.

For a cancer tumour to be able to grow larger than the size of a pea, the cancer cells need to stimulate the formation of new blood vessels that can supply the tumour with oxygen and nutrients, a process known as angiogenesis. A number of medicines which inhibit angiogenesis have been developed, but their effect has been limited, and there is still a major need for better medicines.

The new results concern a receptor on the surface of blood vessel cells called ALK1. When the researchers blocked ALK1 in tumours in mice, angiogenesis was inhibited and the tumours stopped growing. The ALK1 receptor is activated by a family of signalling proteins called TGF-² proteins that are very important for communication between different types of cell in a wide range of key processes in the body. The study indicates that two members of the TGF-β family (TGF-β and BMP9) work together to stimulate angiogenesis in tumours.

ALK1 was blocked partly by genetic means and partly using a pharmaceutical substance called RAP-041.

“We believe that RAP-041 could be used in combination with existing angiogenesis inhibitors to achieve the maximum effect,” says associate professor Kristian Pietras, who led the study.

Clinical studies of ACE-041, the human equivalent of RAP-041, have already been begun in the USA by the company that holds the patent on the substance. One goal of these studies is to find out which types of tumour are most sensitive to ALK1 blockade.

Publication

Sara Cunha, Evangelia Pardali, Midory Thorikay, Charlotte Anderberg, Lukas Hawinkels, Marie-José Goumans, Jasbir Seehra, Carl-Henrik Heldin, Peterten Dijke, Kristian Pietras
Genetic and Pharmacological Targeting of Activin Receptor-like Kinase 1 Impairs Tumor Growth and Angiogenesis

The Journal of Experimental Medicine, 11 January 2010.

Kristian Pietras
Associate Professor of tumour biology

Department of Medical Biochemistry and Biophysics

Mobile: 46 70 920 97 09
E-mail: .(JavaScript must be enabled to view this email address)

Print Version
Tell-a-Friend comments powered by Disqus

RELATED ARTICLES:

New biomarkers may influence drug design and alternative treatments of cancer, study shows   Metabolic profiles distinguish early stage ovarian cancer with unprecedented accuracy   Moffitt researchers develop first genetic test to predict tumor sensitivity to radiation therapy   New drug for neuroblastoma shows promise in phase I study   Experimental treatment sends deadly leukemia into remission   Study could reduce unnecessary cancer screening   UA researchers discover component of cinnamon prevents colorectal cancer in mice   Profiling approach to enable right lung cancer treatment match   Fat grafting technique improves results of breast augmentation   Germline TP53 mutations in patients with early-onset colorectal cancer   Clinical trial suggests combination therapy is best for low-grade brain tumors   UW research shows sensor technology may help improve accuracy of clinical breast exams